Department of Neurosurgery, University Hospital Zurich and Clinical Neuroscience Center, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland.
Neurosurgical Unit 2, Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
J Neurooncol. 2019 Mar;142(1):49-57. doi: 10.1007/s11060-018-03058-y. Epub 2018 Nov 24.
Deciding whether to re-operate patients with intracranial tumor recurrence or remnant is challenging, as the data on safety of repeated procedures is limited. This study set out to evaluate the risks for morbidity, mortality, and complications after repeated operations, and to compare those to primary operations.
Retrospective observational two-center study on consecutive patients undergoing microsurgical tumor resection. The data derived from independent, prospective institutional registries. The primary endpoint was morbidity at 3 months (M3), defined as significant decrease on the Karnofsky Performance Scale (KPS). Secondary endpoints were mortality, rate and severity of complications according to the Clavien-Dindo Grade (CDG).
463/2403 (19.3%) were repeated procedures. Morbidity at M3 occurred in n = 290 patients (12.1%). In univariable analysis, patients undergoing repeated surgery were 98% as likely as patients undergoing primary surgery to experience morbidity (OR 0.98, 95% CI 0.72-1.34, p = 0.889). In multivariable analysis adjusted for age, sex, tumor size, histology and posterior fossa location, the relationship remained stable (aOR 1.25, 95% CI 0.90-1.73, p = 0.186). Mortality was n = 10 (0.4%) at discharge and n = 95 (4.0%) at M3, without group differences. At least one complication occurred in n = 855, and the rate (35.5% vs. 35.9%, p = 0.892) and severity (CDG; p = 0.520) was similar after primary and repeated procedures. Results were reproduced in subgroup analyses for meningiomas, gliomas and cerebral metastases.
Repeated surgery for intracranial tumors does not increase the risk of morbidity. Mortality, and both the rate and severity of complications are comparable to primary operations. This information is of value for patient counseling and the informed consent process.
对于颅内肿瘤复发或残留患者,决定是否再次手术具有挑战性,因为有关重复手术安全性的数据有限。本研究旨在评估再次手术的发病率、死亡率和并发症风险,并与初次手术进行比较。
对连续接受显微肿瘤切除术的患者进行回顾性观察性双中心研究。数据来自独立的、前瞻性的机构登记处。主要终点是术后 3 个月(M3)的发病率,定义为卡氏功能状态量表(KPS)评分显著下降。次要终点是死亡率、并发症的发生率和严重程度,按照 Clavien-Dindo 分级(CDG)进行评估。
463/2403(19.3%)例为重复手术。M3 时发病率为 n=290 例(12.1%)。单变量分析中,再次手术患者发生发病率的可能性与初次手术患者相当(OR 0.98,95%CI 0.72-1.34,p=0.889)。多变量分析调整年龄、性别、肿瘤大小、组织学和后颅窝位置后,关系仍保持稳定(aOR 1.25,95%CI 0.90-1.73,p=0.186)。出院时死亡率为 n=10(0.4%),M3 时死亡率为 n=95(4.0%),两组无差异。n=855 例患者至少发生一次并发症,发生率(35.5%比 35.9%,p=0.892)和严重程度(CDG;p=0.520)在初次手术和重复手术之间相似。脑膜瘤、胶质瘤和脑转移瘤的亚组分析结果一致。
颅内肿瘤再次手术不会增加发病率的风险。死亡率和并发症的发生率及严重程度与初次手术相当。这些信息对于患者咨询和知情同意过程具有重要价值。